Compare Cytokinetics Inc (CYTK) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs GoPro Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while GoPro Inc trades at $1.19 (market cap $253.82M). The key difference: Cytokinetics Inc is far larger — about 33.5× GoPro Inc's market cap, and GoPro Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and GoPro Inc for 45 Days on average.
| CYTK | GPRO | |
|---|---|---|
Market Cap | $8.50B | $253.82M |
Volume | 2,395,556 | 9,909,466 |
Sector | Health | Technology |
52-Week High | $87.26 | $2.35 |
52-Week Low | $54.76 | $0.58 |
Typical Hold Time | 19 Days | 45 Days |
Enterprise Value | $8.60B | $312.60M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
GoPro (GPRO) trades at $1.18, down 10.61% today amid volatile trading following recent merger announcements. The stock shows bullish technical signals with oversold RSI conditions, while fundamentally the company faces significant challenges with negative profit margins and declining revenue. Recent developments include a proposed $285 million merger with Starman Optical and influencer Markiplier taking an 8.5% stake, driving substantial price volatility.
Investment outlook remains highly speculative with the merger offering potential upside from the $1.14 buyout price, but fundamental weakness and negative cash flow pose substantial risks. Analyst sentiment is mixed with only 21% recommending buy, while ongoing investigations into the merger's fairness add uncertainty to the transaction's completion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
